اثر دیمینازین بر هایپرتروفی قلبی از طریق بهبود هایپرلیپیدمی در موش های سفید بزرگ آزمایشگاهی مدل پیری ناشی از د-گالاکتوز

نوع مقاله : مقاله پژوهشی

نویسندگان

1 دانشکده پزشکی، دانشگاه علوم پزشکی همدان، همدان، ایران

2 گروه قلب و عروق، دانشکده پزشکی، دانشگاه علوم پزشکی همدان، همدان، ایران

3 گروه فیزیولوژی، دانشکده پزشکی، دانشگاه علوم پزشکی همدان، همدان، ایران

4 گروه علوم اعصاب، دانشکده علوم و فناوری پیشرفته در پزشکی، دانشگاه علوم پزشکی همدان، همدان، ایران

10.22070/daneshmed.2024.18851.1472

چکیده

مقدمه و هدف: افزایش سن نقش مهمی در بیماری های قلبی عروقی دارد. دیمینازین یک داروی ضد عفونت دامی است که اثرات محافظتی بر بیماری های قلبی عروقی دارد. این مطالعه با هدف بررسی اثرات محافظتی قلبی احتمالی دیمینازین در موش های سفید بزرگ آزمایشگاهی مدل پیری ناشی از د-گالاکتوز از طریق بهبود لاکتات دهیدروژناز (LDH) و کراتین کیناز قلبی (CK-MB) و پروفایل لیپیدی انجام شد.
مواد و روش ها: 20 سر موش سفید بزرگ آزمایشگاهی نر نژاد ویستار به طور مساوی به گروه‌های کنترل،  دیمینازین(DIZE)، د-گالاکتوز (D-GAL) و D-GAL+DIZE تقسیم شدند . هایپرتروفی قلب اندازه گیری شد. سطح سرمی پروفایل لیپیدی و نشانگرهای آسیب قلبی اندازه گیری شد.
نتایج: افزایش سن باعث دیس‌لیپیدمی همراه با هایپرتروفی قلبی و افزایش معنی‌دار LDH و CK-MB سرم شد. درمان  با  دیمینازین در موش های سفید بزرگ آزمایشگاهی پیر باعث بهبود قابل توجهی در هایپرتروفی قلبی و نشانگرهای قلبی شد. این را می توان با توانایی دیمینازین دربهبود سطوح تری گلیسرید(TG) ، لیپوپروتئین با چگالی بسیار کم (VLDL) و لیپوپروتئین با چگالی بالا (HDL) توضیح داد.
نتیجه‌گیری: دیمینازین  اثر محافظتی قلبی در پیری، عمدتاً با بهبود هایپرتروفی قلبی و دیس‌لیپیدمی دارد.

کلیدواژه‌ها

موضوعات


عنوان مقاله [English]

Effect of diminazene on cardiac hypertrophy through improving hyperlipidemia in D-galactose-induced aging rats

نویسندگان [English]

  • Ali Mohammadi 1
  • Farnaz Fariba 2
  • Siamak Shahidi 3
  • Abdolrahman Sarihi 4
  • Fatemeh Ramezani-Aliakbari 3
1 Medical School, Hamadan University of Medical Sciences, Hamadan, Iran
2 Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
3 Department of Physiology, School of medicine, Hamadan University of Medical Sciences, Hamadan, Iran
4 Department of Neuroscience, School of Sciences and Advanced Technology in Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
چکیده [English]

Background and Objective: Aging plays an important role in cardiovascular diseases. Diminazine is an animal anti-infective drug that has protective effects on cardiovascular diseases. This study aimed to investigate the possible cardio-protective effects of Diminazine in aged rats induced by D-galactose through improving lactate dehydrogenase (LDH), and cardiac creatine kinase (CK-MB), and lipid profile.
Materials and Methods: 20 male Wistar rats were divided equally into control, Diminazine (DIZE), D-galactose (D-GAL), and D-GAL+DIZE groups. Cardiac hypertrophy was measured. Serum levels of lipid profile and cardiac damage markers were also measured.
Results: Aging caused dyslipidemia with cardiac hypertrophy and significant increases in serum LDH, and CK-MB. Diminazine treatment of aged rats induced significant improvements in cardiac hypertrophy and cardiac markers. This could be explained by the ability of Diminazine to improve triglyceride (TG), very low density lipoprotein (VLDL), and high density lipoprotein (HDL) levels.
Conclusion: Diminazine exerts a cardio-protective effect in aging, mainly by improving cardiac hypertrophy and dyslipidemia.

کلیدواژه‌ها [English]

  • Aging
  • Diminazine
  • Heart
  • Hypertrophy
  1. Niccoli T, Partridge L. Ageing as a risk factor for disease. Current Biology 2012;22(17):R741-R52.
  2. Tasatargil A, Kuscu N, Dalaklioglu S, Adiguzel D, Celik-Ozenci C, Ozdem S, et al. Cardioprotective effect of nesfatin-1 against isoproterenol-induced myocardial infarction in rats: role of the Akt/GSK-3β pathway. Peptides 2017;95:1-9.
  3. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radical Biology and Medicine 2000;29(3-4):222-230.
  4. Cadenas S. Mitochondrial uncoupling, ROS generation and cardioprotection. Biochimica et Biophysica Acta -Bioenergetics 2018;1859(9):940-950.
  5. Klimiuk A, Zalewska A, Sawicki R, Knapp M, Maciejczyk M. Salivary oxidative stress increases with the progression of chronic heart failure. Journal of Clinical Medicine 2020;9(3):769.
  6. Sun S-L, Guo L, Ren Y-C, Wang B, Li R-H, Qi Y-S, et al. Anti-apoptosis effect of polysaccharide isolated from the seeds of Cuscuta chinensis Lam on cardiomyocytes in aging rats. Molecular Biology Reports 2014;41:6117-6124.
  7. Cebe T, Yanar K, Atukeren P, Ozan T, Kuruç AI, Kunbaz A, et al. A comprehensive study of myocardial redox homeostasis in naturally and mimetically aged rats. Age. 2014;36:1-14.
  8. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Advances in Pharmacology 1992;23:1-34.
  9. Chang Y-M, Chang H-H, Kuo W-W, Lin H-J, Yeh Y-L, Padma Viswanadha V, et al. Anti-apoptotic and pro-survival effect of alpinate oxyphyllae fructus (AOF) in a d-galactose-induced aging heart. International Journal of Molecular Sciences. 2016;17(4):466.
  10. Parini P, Angelin B, Rudling M. Cholesterol and lipoprotein metabolism in aging: reversal of hypercholesterolemia by growth hormone treatment in old rats. Arteriosclerosis, Thrombosis, and Vascular Biology 1999;19(4):832-839.
  11. Bey L, Hamilton MT. Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low‐intensity activity. The Journal of Physiology 2003;551(2):673-682.
  12. Rubio-Ruíz M, Del Valle-Mondragón L, Castrejón-Tellez V, Carreón-Torres E, Díaz-Díaz E, Guarner-Lans V. Angiotensin II and 1-7 during aging in Metabolic Syndrome rats. Expression of AT1, AT2 and Mas receptors in abdominal white adipose tissue. Peptides 2014;57:101-108.
  13. Bruce EB, Sakarya Y, Kirichenko N, Toklu HZ, Sumners C, Morgan D, et al. ACE2 activator diminazene aceturate reduces adiposity but preserves lean mass in young and old rats. Experimental Gerontology 2018;111:133-140.
  14. Joviano‐Santos JV, Santos‐Miranda A, Joca HC, Cruz JS, Ferreira AJ. Diminazene aceturate (DIZE) has cellular and in vivo antiarrhythmic effects. Clinical and Experimental Pharmacology and Physiology 2020;47(2):213-219.
  15. Da Silva Oliveira GL, de Freitas RM. Diminazene aceturate—An antiparasitic drug of antiquity: Advances in pharmacology & therapeutics. Pharmacological Research 2015;102:138-157.
  16. Velkoska E, Patel SK, Griggs K, Burrell LM. Diminazene aceturate improves cardiac fibrosis and diastolic dysfunction in rats with kidney disease. PLoS One 2016;11(8):e0161760.
  17. Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V, Espejo A, Hanna M, et al. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension 2013;62(4):746-752.
  18. Chang Y-M, Chang H-H, Lin H-J, Tsai C-C, Tsai C-T, Chang H-N, et al. Inhibition of cardiac hypertrophy effects in d-galactose-induced senescent hearts by alpinate oxyphyllae fructus treatment. Evidence-Based Complementary and Alternative Medicine 2017.
  19. Javidanpour S, Dianat M, Badavi M, Mard SA. The inhibitory effect of rosmarinic acid on overexpression of NCX1 and stretch-induced arrhythmias after acute myocardial infarction in rats. Biomedicine & Pharmacotherapy 2018;102:884-893.
  20. Shackebaei D, Hesari M, Ramezani-Aliakbari S, Hoseinkhani Z, Ramezani-Aliakbari F. Gallic acid protects against isoproterenol-induced cardiotoxicity in rats. Human & Experimental Toxicology 2022; 41:9603271211064532. doi: 10.1177/09603271211064532.
  21. Shackebaei D, Hesari M, Ramezani-Aliakbari S, Pashaei M, Yarmohammadi F, Ramezani-Aliakbari F. Cardioprotective effect of naringin against the ischemia/reperfusion injury of aged rats. Naunyn-Schmiedeberg's Archives of Pharmacology 2023:1-10.
  22. Shahidi S, Ramezani-Aliakbari K, Komaki A, Salehi I, Hashemi S, Asl SS, et al. Effect of vitamin D on cardiac hypertrophy in D-galactose-induced aging model through cardiac mitophagy. Molecular Biology Reports 2023; 50(12):10147-10155.
  23. Zarei M, Sarihi A, Zamani A, Raoufi S, Karimi SA, Ramezani-Aliakbari F. Mitochondrial biogenesis and apoptosis as underlying mechanisms involved in the cardioprotective effects of Gallic acid against D-galactose-induced aging. Molecular Biology Reports 2023;50(10):8005-8014.
  24. Wang J, Bai Y, Zhao X, Ru J, Kang N, Tian T, et al. oxLDL-mediated cellular senescence is associated with increased NADPH oxidase p47phox recruitment to caveolae. Bioscience Reports 2018;38(3):BSR20180283.
  25. Ahmad F, Leake DS. Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages [S]. Journal of Lipid Research 2019;60(1):98-110.
  26. Liu H-H, Li J-J. Aging and dyslipidemia: a review of potential mechanisms. Ageing Research Reviews 2015;19:43-52.
  27. Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circulation: Cardiovascular Interventions 2010;3(6):602-610.
  28. Reddy RK, Reddy S, Kumar AN. Lipid Profile levels on the second day of Acute Myocardial Infarction; is it the right time for estimation? Internet Journal of Medical Update-Ejournal 2012;7(1).
  29. Patil N, Chavan V, Karnik N. Antioxidant status in patients with acute myocardial infarction. Indian Journal of Clinical Biochemistry 2007;22:45-51.
  30. Park K-H, Kim J-Y, Choi I, Kim J-R, Won KC, Cho K-H. Fructated apolipoprotein AI exacerbates cellular senescence in human umbilical vein endothelial cells accompanied by impaired insulin secretion activity and embryo toxicity. Biochemistry and Cell Biology 2016;94(4):337-345.
  31. Lu J, Jiang W, Yang J-H, Chang P-Y, Walterscheid JP, Chen H-H, et al. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 2008;57(1):158-166.
  32. Tai M-H, Kuo S-M, Liang H-T, Chiou K-R, Lam H-C, Hsu C-M, et al. Modulation of angiogenic processes in cultured endothelial cells by low density lipoproteins subfractions from patients with familial hypercholesterolemia. Atherosclerosis 2006;186(2):448-457.
  33. Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation, aging, and cardiovascular disease: JACC review topic of the week. Journal of the American College of Cardiology 2022;79(8):837-847.
  34. Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. The journal of physiology. 2020;598(14):2977-93.
  35. Gendelis S, Inbar D, Inbar K, Mesner S, Kupchik YM. Metaplasticity in the ventral pallidum as a potential marker for the propensity to gain weight in chronic high-calorie diet. Journal of Neuroscience 2020;40(50):9725-9735.
  36. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995;115(2):201-215.
  37. Sugimoto K, Kazdova L, Qi NR, Hyakukoku M, Kren V, Šimáková M, et al. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-γ dependent pathway. Journal of Hypertension 2008;26(6):1209-1215.
  38. Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, Derosa G. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. European Journal of Gastroenterology & Hepatology 2012;24(2):164-171.
  39. Shokri F, Zarei M, Komaki A, Raoufi S, Ramezani-Aliakbari F. Effect of diminazene on cardiac hypertrophy through mitophagy in rat models with hyperthyroidism induced by levothyroxine. Naunyn-Schmiedeberg's Archives of Pharmacology 2024;397(2):1151-1162.
  40. Castardeli C, Sartório CL, Pimentel EB, Forechi L, Mill JG. The ACE 2 activator diminazene aceturate (DIZE) improves left ventricular diastolic dysfunction following myocardial infarction in rats. Biomedicine & Pharmacotherapy 2018;107:212-218.
  41. Dai D-F, Rabinovitch PS. Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. Trends in Cardiovascular Medicine 2009;19(7):213-220.
  42. Ramachandra CJ, Cong S, Chan X, Yap EP, Yu F, Hausenloy DJ. Oxidative stress in cardiac hypertrophy: From molecular mechanisms to novel therapeutic targets. Free Radical Biology and Medicine 2021;166:297-312.
  43. Girotti AW. Mechanisms of lipid peroxidation. Journal of Free Radicals in Biology & Medicine 1985;1(2):87-95.
  44. Hassan MQ, Akhtar MS, Akhtar M, Ali J, Haque SE, Najmi AK. Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence. Redox Report 2015;20(6):275-281.
  45. Chen J, Cui L, Yuan J, Zhang S, Ma R, Sang H, et al. Protective effect of diminazene attenuates myocardial infarction in rats via increased inflammation and ACE2 activity. Molecular Medicine Reports 2017;16(4):4791-4796.